WebSep 15, 2024 · The multicenter DEB-DRAGON Registry enrolled 1,117 consecutive patients with DES ISR between 2008 and 2024. Around half received a paclitaxel DCB: Agent … WebThe Agent DCB uses an inactive excipient to effectively deliver a targeted, therapeutic dose of paclitaxel to the vessel wall. Study design: A total of 480 patients with ISR of a …
33 Leyden St #4, Boston, MA 02128 MLS #73098683 Zillow
WebJul 23, 2014 · The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel … WebMay 30, 2014 · drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion Device: Agent Paclitaxel-coated balloon After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion. bank nagari internet banking
Catheter Delivery System & Guide - Boston Scientific
WebMay 12, 2024 · The U.S. prospective, randomized clinical trial will evaluate the safety and effectiveness of a drug-coated balloon (DCB) in patients with coronary in-stent restenosis in lesions up to 26 mm in length in a coronary artery 2.0 mm to 4.0 mm in diameter. Get the full story at our sister site, Medical Tubing & Extrusion. WebBoston Scientific's Ranger Drug-Coated Balloon is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform¹ with the lowest tip entry profile of any SFA DCB². For ease, durability and effectiveness, Ranger … WebNov 1, 2024 · Drug-coated balloon (DCB) technology was developed as an alternative treatment for obstructive coronary artery disease (CAD) and in-stent restenosis (ISR). Management of coronary ISR is clinically challenging and frequently encountered in practice. bank mutual eau claire